# Psychedelic Drug Clinical Trials Update – April 2026 > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/psychedelic-drug-clinical-trials-april-2026/ > **Published:** 2026-04-18T23:07:23-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:18:36-04:00 > **Clinical Summary:** Explore the latest on psychedelic drug clinical trials and research updates relevant to cannabis clinicians in April 2026. --- In the Mix — Last 24 HoursApril 18, 2026. 10 articles reviewed below the CED clinical relevance threshold of 35. Listed in descending order of score. #25 [Trump signs order to accelerate access to psychedelic drug treatments | Reuters](https://www.reuters.com/world/trump-announces-reforms-accelerate-access-psychedelic-drug-treatments-2026-04-18/) Article covers Trump administration’s executive order accelerating psychedelic drug [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) and federal ibogaine research funding, relevant to cannabis clinicians monitoring broader psychoactive substance policy shifts. [Read more →](https://www.reuters.com/world/trump-announces-reforms-accelerate-access-psychedelic-drug-treatments-2026-04-18/) #25 [Three Rocky Mount vape shops accused of selling illegal cannabis-related products](https://www.wdbj7.com/2026/04/18/three-rocky-mount-vape-shops-accused-selling-illegal-cannabis-related-products/?outputType=amp) Three vape shops face accusations of selling cannabis products exceeding Virginia’s legal THC limits, potentially relevant to clinicians tracking regulatory enforcement and product compliance issues. [Read more →](https://www.wdbj7.com/2026/04/18/three-rocky-mount-vape-shops-accused-selling-illegal-cannabis-related-products/?outputType=amp) #25 [Jimmy Buffett CBD Gummies: A Practical Look at the Laid-Back Wellness Option](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/2W6hHG) This article discusses CBD gummies marketed under a celebrity brand and references a UK study on CBD use for anxiety, though lacks detailed clinical evidence or efficacy data. [Read more →](https://www.qsr.mlit.go.jp/kikuti/pannellum/pannellum.htm?config=/%5C/ccc1.sbs/article/cbd2/2W6hHG) #15 [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://www.marijuanamoment.net/trump-signs-order-to-accelerate-legal-access-to-psychedelics-for-patients-with-mental-health-conditions/) Trump administration executive order aims to accelerate psychedelic research and patient access in clinical settings, relevant as cannabis clinicians may encounter patients using multiple psychoactive substances therapeutically. [Read more →](https://www.marijuanamoment.net/trump-signs-order-to-accelerate-legal-access-to-psychedelics-for-patients-with-mental-health-conditions/) #15 [How Cheech & Chong lit up the film industry – Salon.com](https://www.salon.com/2026/04/18/how-cheech-chong-lit-up-the-film-industry/) This article discusses the cultural impact of Cheech & Chong’s comedies in relation to evolving marijuana legalization trends and cannabis’s increased mainstream visibility. [Read more →](https://www.salon.com/2026/04/18/how-cheech-chong-lit-up-the-film-industry/) #15 [Colorado Springs dispensaries mark first year of retail marijuana sales](https://gazette.com/2026/04/18/colorado-springs-dispensaries-mark-first-year-of-retail-marijuana-sales/) This article reports on Colorado Springs’ first year of legal retail marijuana operations, documenting 62 issued licenses, which may interest clinicians tracking regulatory implementation and market development patterns. [Read more →](https://gazette.com/2026/04/18/colorado-springs-dispensaries-mark-first-year-of-retail-marijuana-sales/) Digest-Level Clinical Commentary Dr. Caplan’s Take These digest items reflect a fragmented regulatory landscape where [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) practice must navigate simultaneously expanding psychedelic research pathways, inconsistent state-level THC potency enforcement, and persistent public health concerns about product mislabeling and youth-accessible packaging. The clinical challenge ahead lies in distinguishing legitimate therapeutic applications from recreational marketing while evidence for [cannabis dosing](https://cedclinic.com/medical-cannabis-safety-facts/), cannabinoid ratios, and patient safety profiles remains incomplete relative to other pharmaceutical interventions. Moving forward, cannabis practitioners will need robust patient education frameworks and clear documentation standards to operate ethically within this evolving legal and scientific environment. Clinical Perspective These items reflect several concurrent developments in cannabis and related substance policy: expanding federal interest in psychedelic research and treatment access, ongoing state-level regulatory challenges around cannabis product standardization and marketing (particularly concerning products marketed to or resembling those for children), and the cultural normalization of [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) reflected in mainstream media engagement and retail expansion. The clinical landscape is characterized by a growing disconnect between evolving legal frameworks at state and federal levels and the need for clear, evidence-based guidance on product safety, potency standardization, and appropriate clinical applications. Healthcare providers should be aware of these regulatory shifts and emerging products, particularly products containing cannabinoid analogs like THCA that may circumvent existing restrictions while creating uncertainty around actual THC exposure and patient safety. RegulationLegalizationConsumer ProductsPublic Health[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/) 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+In+the+Mix+%E2%80%94+April+18%2C+2026+%40drcaplan&url=)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+In+the+Mix+%E2%80%94+April+18%2C+2026+--+via+%40drcaplan.bsky.social+)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Trump signs order to accelerate access to psychedelic drug treatments – Reuters](https://cedclinic.com/psychedelic-drug-treatments-policy-accelerate-access-trump/) - [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) - [CED Digest: 230 Items — March 18, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Trump Signs Order To Accelerate Legal Access To Psychedelics For Patients With Mental …](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) Details on the executive order aimed at speeding up patient access to psychedelic treatments. [Read More](https://cedclinic.com/accelerate-psychedelic-assisted-therapies-mental-health-access/) [Joe Rogan praises Trump's executive order on psychedelics research | Watch – MSN](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/) Coverage of public figures supporting the new federal psychedelic research initiatives. [Watch Now](https://cedclinic.com/psychedelic-research-funding-impact-trump-executive-order/) [Trump signs order to accelerate access to psychedelic drug treatments – Reuters](https://cedclinic.com/psychedelic-drug-treatments-policy-accelerate-access-trump/) Reuters report on the federal push to fast-track psychedelic drug treatment research. [Learn More](https://cedclinic.com/psychedelic-drug-treatments-policy-accelerate-access-trump/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).